SOURCE: StockCall


November 15, 2010 08:29 ET

Equity Research on Celgene Corporation and Amgen Inc. - Biotech Trends for the Third Quarter

JOHANNESBURG, SOUTH AFRICA--(Marketwire - November 15, 2010) - offers investors comprehensive research on the biotechnology industry and has completed analytical research on Celgene Corporation (NASDAQ: CELG) and Amgen Inc. (NASDAQ: AMGN). Register with us today at to have free access to these researches. 

Biotech companies specializing in the development and manufacturing of cancer treatment medications such as Celgene Corporation performed slightly better than the drug industry as a whole during the last quarter. Cancer treatment manufacturers have not been hit as hard by the drops in demand seen by many in the industry. It appears that consumers have demonstrated a willingness to postpone elective procedures or opt for generic medications for some illnesses, but not for cancer treatments. Celgene Corporation research report is accessible for free by registering today at is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Celgene Corporation and Amgen Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

However, some of the problems the whole industry is facing have negatively impacted cancer treatment companies as well. Currency fluctuations have adversely affected global revenues and healthcare reform has also dented revenues during the last quarter. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future. Register now at to have free access to our reports on the biotechnology industry.

Like most other segments of the drug industry, research and development spending has been a good litmus test for cancer treatment manufacturers. While manufacturers of cancer medication haven't had to contend with significant demand drops, increased competition still remains an issue.

Moving forward, steady demand has been a positive for the industry but increased competition, currency fluctuations and healthcare reform continue to challenge consistent profits and growth. 

For Q3 2010, Amgen Inc. posted a 11% decline in profit on the back of a weak sales of its osteoporosis drug and an elevated operating cost. Earnings came in at $1.24 billion on a revenue surge to $3.82 billion. Amgen Inc. research report is available for free by signing up now at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information